Metilnaltreksonijev bromid
Methylnaltrexone bromide

new target medicine, its importance in palliative care

Authors

  • Jožica Červek Onkološki inštitut, Ljubljana

Keywords:

methylnaltrexone bromide, opioids, MNTX, opioid-induced constipation

Abstract

Metilnaltreksonijev bromid (Relistor) je selektiven periferni antagonist vezave opioidov na receptorje. Uporablja se za zdravljenje zaprtja, ki je nastalo zaradi opioidov, kadar običajna odvajala niso učinkovita. MNTX ne vpliva na protibolečinski učinek opioidov. MNTX je novo tarčno zdravilo, ki ciljano blokira mehanizem z opioidi povzročenega zaprtja. Zaradi navedenih lastnosti omogoča optimalno obravnavo bolečine, ker odpravlja neobvladljivo zaprtje. Bolniku omogoča opravljanje vsakodnevnih dejavnosti in v zadnjem obdobju izboljša kakovost njegovega življenja. Neželeni učinki so manjši od dobrobiti (7). Zaradi navedenega so odgovorne ustanove odobrile MNTX za klinično uporabo

Abstract (Eng)

No abstract.

Downloads

Published

2008-12-15

How to Cite

Červek, J. (2008). Methylnaltrexone bromide: new target medicine, its importance in palliative care. Onkologija : A Medical-Scientific Journal, 12(2), 135–136. Retrieved from https://revijaonkologija.si/Onkologija/article/view/387

Issue

Vol. 12 No. 2 (2008)

Section

Review Article

License

The journal is published under the terms of the Creative Commons Attribution License CC-BY 4.0. The authors retain the copyright to their work without any restrictions whatsoever.

This journal is an open-access journal, meaning that all of its contents are freely accessible without any charge to the user or their institution. In accordance with the Budapest Open Access Initiative (BOAI) definition of open access, users are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking for prior permission from the publisher or the author, provided the authors and the journal are appropriately credited.